Publication date: Aug 12, 2019
This post was originally published on this site A draft guidance issued by the National Institute for Health and Care Excellence (NICE), a U. K. advisory board, and a review by England’s National Health Service (NHS) call for more research into medical cannabis for multiple sclerosis and other conditions. Eight separate recommendations for further research were made across all indications and products covered, which NICE said reflected an overall lack of evidence of clinical benefit and cost-effectiveness regarding these products. The guidance also recommends against using other options for the same purpose outside of a clinical trial because of -a lack of clear evidence that these treatments provide any benefits,” NICE states in its press release. Sativex and nabilone are the only cannabis-based medicines licensed for use by adults in the U. K., NICE notes in its draft guidance. The post NICE and NHS England Oppose Sativex to Treat Spasticity in MS, Urge More Studies of Medical Cannabis appeared first on Multiple Sclerosis News Today. The post NICE and NHS England Oppose Sativex to Treat Spasticity in MS, Urge More Studies of Medical Cannabis appeared first on BioNewsFeeds.